|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CGA |
Gene summary for CGA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CGA | Gene ID | 1081 |
| Gene name | glycoprotein hormones, alpha polypeptide | |
| Gene Alias | CG-ALPHA | |
| Cytomap | 6q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P01215 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1081 | CGA | GSM4909307 | Human | Breast | IDC | 1.11e-28 | 6.67e-01 | 0.1569 |
| 1081 | CGA | GSM4909308 | Human | Breast | IDC | 1.19e-15 | 3.73e-01 | 0.158 |
| 1081 | CGA | GSM4909319 | Human | Breast | IDC | 1.48e-02 | 2.39e-01 | 0.1563 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004873214 | Breast | IDC | gland development | 64/1434 | 436/18723 | 3.47e-07 | 1.74e-05 | 64 |
| GO:004860812 | Breast | IDC | reproductive structure development | 60/1434 | 424/18723 | 2.71e-06 | 1.03e-04 | 60 |
| GO:006145813 | Breast | IDC | reproductive system development | 60/1434 | 427/18723 | 3.41e-06 | 1.24e-04 | 60 |
| GO:001921612 | Breast | IDC | regulation of lipid metabolic process | 45/1434 | 331/18723 | 1.21e-04 | 2.24e-03 | 45 |
| GO:0008406 | Breast | IDC | gonad development | 32/1434 | 221/18723 | 3.64e-04 | 5.23e-03 | 32 |
| GO:00192184 | Breast | IDC | regulation of steroid metabolic process | 18/1434 | 100/18723 | 5.40e-04 | 6.96e-03 | 18 |
| GO:0045137 | Breast | IDC | development of primary sexual characteristics | 32/1434 | 227/18723 | 5.85e-04 | 7.44e-03 | 32 |
| GO:00468904 | Breast | IDC | regulation of lipid biosynthetic process | 26/1434 | 171/18723 | 5.92e-04 | 7.50e-03 | 26 |
| GO:00508102 | Breast | IDC | regulation of steroid biosynthetic process | 14/1434 | 69/18723 | 6.37e-04 | 7.94e-03 | 14 |
| GO:00066944 | Breast | IDC | steroid biosynthetic process | 25/1434 | 173/18723 | 1.56e-03 | 1.56e-02 | 25 |
| GO:0007548 | Breast | IDC | sex differentiation | 35/1434 | 276/18723 | 2.23e-03 | 2.07e-02 | 35 |
| GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
| GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
| GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
| GO:00075689 | Cervix | CC | aging | 75/2311 | 339/18723 | 2.75e-07 | 1.13e-05 | 75 |
| GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
| GO:00313494 | Cervix | CC | positive regulation of defense response | 60/2311 | 278/18723 | 9.38e-06 | 2.11e-04 | 60 |
| GO:00028315 | Cervix | CC | regulation of response to biotic stimulus | 67/2311 | 327/18723 | 1.79e-05 | 3.36e-04 | 67 |
| GO:00075695 | Cervix | CC | cell aging | 34/2311 | 132/18723 | 1.92e-05 | 3.53e-04 | 34 |
| GO:00096158 | Cervix | CC | response to virus | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CGA | SNV | Missense_Mutation | c.30N>G | p.Ile10Met | p.I10M | protein_coding | deleterious_low_confidence(0.02) | benign(0.295) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CGA | SNV | Missense_Mutation | novel | c.232N>A | p.Ala78Thr | p.A78T | protein_coding | tolerated(0.53) | benign(0.121) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CGA | SNV | Missense_Mutation | c.433C>G | p.His145Asp | p.H145D | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-C5-A1BF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | ||
| CGA | SNV | Missense_Mutation | rs145503313 | c.322N>A | p.Val108Ile | p.V108I | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CGA | SNV | Missense_Mutation | novel | c.373N>A | p.Val125Ile | p.V125I | protein_coding | tolerated(0.52) | benign(0.073) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CGA | SNV | Missense_Mutation | c.185N>A | p.Cys62Tyr | p.C62Y | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| CGA | SNV | Missense_Mutation | c.317N>C | p.Lys106Thr | p.K106T | protein_coding | deleterious(0) | possibly_damaging(0.836) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| CGA | SNV | Missense_Mutation | novel | c.4N>A | p.Asp2Asn | p.D2N | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.856) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CGA | SNV | Missense_Mutation | c.297N>T | p.Lys99Asn | p.K99N | protein_coding | deleterious(0.05) | possibly_damaging(0.51) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CGA | SNV | Missense_Mutation | rs745838602 | c.407N>T | p.Ala136Val | p.A136V | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-D1-A15W-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | VINBLASTINE | VINBLASTINE | 6181870 | |
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | 4-{([(4'-CHLOROPHENYL)AMINO]CARBONYLAMINO)}BENZENESULFONAMIDE | CHEMBL1446150 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | CIS-DIAMMINEDICHLOROPLATINUM | 6181870 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | TUMOR NECROSIS FACTOR | 9764349,10788437 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | IL-18 | 11712764 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | 9-CIS-RETINOIC ACID | 8070357 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | TESTOSTERONE | TESTOSTERONE | 1157041 | |
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | CORTICOSTEROIDS | 3106008 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |